- Home
- TKC vs LEGN Comparison
TKC vs LEGN Comparison
Compare TKC & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TKC | LEGN |
|---|---|---|
| Founded | 1993 | 2014 |
| Country | | US |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 5.9B |
| IPO Year | 2001 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TKC | LEGN |
|---|---|---|
| Price | $7.03 | $18.40 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $63.46 |
| AVG Volume (30 Days) | 794.7K | ★ 2.8M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.24% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $43.64 | $67.72 |
| Revenue Next Year | $28.36 | $43.82 |
| P/E Ratio | $26.98 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.35 | $16.24 |
| 52 Week High | $7.60 | $45.30 |
Technical Indicators
Market Signals| Indicator | TKC | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 70.79 | 45.11 |
| Support Level | $7.02 | $17.56 |
| Resistance Level | $7.18 | $17.38 |
| Average True Range (ATR) | 0.11 | 0.76 |
| MACD | 0.02 | 0.31 |
| Stochastic Oscillator | 80.39 | 89.11 |
Price Performance
Historical ComparisonAbout TKC Turkcell Iletisim Hizmetleri AS
Turkcell Iletisim Hizmetleri AS provides mobile telephone services in Turkey. The firm's services portfolio includes high-quality mobile and fixed voice, data, TV, and digital services over its network. The firm also operates in the Turkish Republic of Northern Cyprus, Belarus, the Netherlands, and Ukraine. It has three main reportable segments: Turkcell Turkiye, Turkcell International, and Techfin. The Turkcell Turkiye segment, which derives the majority of revenue, comprises mainly telecommunication and technology services activities.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.